BMJ 2003;327 (25 October), doi:10.1136/bmj.327.7421.0-d
Hydralazine is not the best antihypertensive in pregnancy
Hydralazine is less effective than nifedipine or isradipine for treating severe hypertension in pregnancy. In a meta-analysis of randomised controlled trials published in 1966-2002, Magee and colleagues (p 955) analysed data from 21 trials that included 893 women with severe hypertension in pregnancy. Although not robust enough to guide clinical practice, the results do not support the use of hydralazine as first line treatment of severe hypertension in pregnancy. Compared with other antihypertensives, hydralazine was associated with more maternal, fetal, and perinatal adverse side effects.
CiteULike 
Complore 
Connotea 
Del.icio.us 
Digg 
Reddit 
StumbleUpon 
Technorati What's this?
Relevant Article
- Hydralazine for treatment of severe hypertension in pregnancy: meta-analysis
- Laura A Magee, Chris Cham, Elizabeth J Waterman, Arne Ohlsson, and Peter von Dadelszen
BMJ 2003 327: 955.[Abstract] [Full Text] [PDF]
This Article
- Respond to this article
- Alert me when this article is cited
- Alert me when responses are posted
- Alert me when a correction is posted
Services
- Email this article to a friend
- Find similar articles in BMJ
- Add article to my folders
- Download to citation manager
- Request Permissions
Citing Articles
Google Scholar
Related Content
Bookmark with
What's new
Latest blogs
Find BMJ on:
Services
Tools
Online poll
Resources
Rapid responses for this article
There are no rapid responses for this article. Print issues
